Humanized ANTI-CXCR5 Antibodies, Derivatives Thereof and Their Use
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application 12/675,799, filed Oct 25, 2010. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,980,262 | Humanized ANTI-CXCR5 Antibodies, Derivatives Thereof and Their Use In force · High confidence | Sanofi | In force | High confidence | ||
| US 9,175,087 | Humanized Anti-CXCR5 Antibodies, Derivatives Thereof And Their Use In force · High confidence | Sanofi | In force | High confidence | ||
| US 9,228,019 | Humanized ANTI-CXCR5 Antibodies, Derivatives Thereof and Their Use In force · High confidence | Sanofi | In force | High confidence | ||
| US 9,243,067 | Humanized Anti-CXCR5 Antibodies, Derivatives Thereof And Their Use In force · High confidence | Sanofi | In force | High confidence | ||
| US 9,815,902 | Humanized Anti-CXCR5 Antibodies, Derivatives Thereof and Their Uses In force · High confidence | Sanofi | In force | High confidence | ||
| US 12,655,222 | Humanized Anti-CXCR5 Antibodies, Derivatives Thereof and Their Uses In force · High confidence | Sanofi | In force | High confidence | ||
| US 8,647,622 | Humanized anti-CXCR5 antibodies, derivatives thereof and their use In force · High confidence | Sanofi | In force | High confidence | ||
| Application 13/794,253 | Humanized Anti-CXCR5 Antibodies, Derivatives Thereof And Their Use Abandoned Abandoned Nov 28, 2016 | Sanofi | Abandoned | Abandoned Nov 28, 2016 | ||
| Application 15/725,253 | Humanized Anti-CXCR5 Antibodies, Derivatives Thereof and Their Use Abandoned Abandoned Oct 26, 2021 | Sanofi-Aventis | Abandoned | Abandoned Oct 26, 2021 |
9 of 9 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Sanofi-Aventis.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.